Increased expression of costimulatory molecules CD86 and sCTLA-4 in patients with acute lymphoblastic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2120-2124

  Mansour, Amany ^a   Elkhodary, Tawfik ^a   Darwish, Ahmad ^a   Mabed, Mohamed ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Acute lymphoblastic leukemia; CD86; Immunophenotype; SCTLA 4

Indexed keywords

CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; MORTALITY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROGNOSIS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD86; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CTLA-4 ANTIGEN; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; YOUNG ADULT;

EID: 84906064988     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.869328     Document Type: Article

References (35)

1. Pui CH, Relling MV, D owning JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Van Dongen JJ, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
3. Coustan-Smith E, Sancho J, Hancock M L, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
4. Volpi C, Salomon B L, Fioretti M C, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004; 5: 1134-1142.
5. Brigl M, Brenner MB. CD1 antigen presentation and T cell function. Annu Rev Immunol 2004; 22: 817-890.
6. Kummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996; 183: 2533-2540.
7. Greenwald RJ, Oosterwegel MA, van der Woude D, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002; 32: 366-373.
8. M erlo A, T enca C, F ais F, et al. Inhibitory receptors CD85j, LAIR-1, and CD152 down-regulate immunoglobulin and cytokine production by human B lymphocytes. Clin Diagn Lab Immunol 2005; 12: 705-712
9. Hirano N, Takahashi T, Ohtake S, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004; 5: 1134-1142.
10. H ock B D, P atton W N, B udhia S, et al. Human plasma contains a soluble form of CD86 which is present at elevated levels in some leukemia patients. Leukemia 2002; 16: 865-873.
11. Barrett A J, L e Blanc K. I mmunotherapy prospects for acute myeloid leukaemia. Clin Exp Immunol 2010; 161: 223-232.
12. Contardi E, Palmisano GL, Tazzari PL, et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005; 117: 538-550.
13. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1: 405-413.
14. O gura M, O mine M, S aito T, et al. Expression of costimulatory molecules in human leukemias. Leukemia 1996; 10: 1168-1176.
15. Hodi FS, Mihm MC, Soiffer RJ, et al. Soluble CD86 is a costimulatory molecule for human T lymphocytes. Immunity 2000; 13: 303-312.
16. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27: 5168-5174.
17. L aurent S, C arrega P, S averino D, et al. CTLA-4 is expressed by human monocyte-derived DCs and its ligation modulates cytokine secretion and T cell proliferation stimulating ability. Hum Immunol 2010; 71: 934-941.
18. Maeda A, Yamamoto K, Yamashita K, et al. The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2- positive leukemia. Br J Haematol 1998; 102: 1257-1262.
19. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277.
20. Z hou J, G oldwasser M A, L i A, et al.; D ana-Farber Cancer Institute ALL Consortium. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood 2007; 110: 1607-1611
21. S imone R, T enca C, F ais F, et al. A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression. PLoS One 2012; 7: e44654.
22. Sun T, Hu Z, Shen H, et al. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res 2009; 69: 6011-6014.
23. K itawaki T, K adowaki N, F ukunaga K, et al. Cross-priming of CD8 T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia. Exp Hematol 2011; 39: 424-433.
24. Levings MK, Sangregorio R, Sartirana C, et al. Human CD25+ CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med 2002; 196: 1335-1346.
25. Hou R, Cao B, Chen Z, et al. Association of cytotoxic T lymphocyteassociated antigen-4 gene haplotype with the susceptibility to gastric cancer. Mol Biol Rep 2010; 37: 515-520.
26. Pistillo MP, Tazzari PL, Palmisano GL, et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003; 101: 202-209.
27. Expressions and significance of CD80, CD86 and ICAM-1 on acute leukemic cells. By STMOPEN.net on Monday. 2013, March 18. Available from: http://www.stmopen.net/category/journals/chinesemedicinal- biotechnology/
28. Wong CK, Lun SWN, Ko FWS, et al. Increased expression of plasma and cell surface co-stimulatory molecules CTLA-4, CD28 and CD86 in adult patients with allergic asthma. Clin Exp Immunol 2005; 141: 122-129.
29. Lion E, Willemen Y, Berneman ZN, et al. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012; 26: 2019-2026.
30. Laurent S, Carrega P, Saverino D, et al. CTLA-4 is expressed by human monocyte-derived DCs and its ligation modulates cytokine secretion and T cell proliferation stimulating ability. Hum Immunol 2010; 71: 934-941.
31. Simone R, Tenca C, Fais F, et al. A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression. PLoS One 2012; 7: e44654.
32. Pawlak E, Karabon L, Wlodarska-Polinska I, et al. Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol 2010; 71: 195-200.
33. Zheng Z, T akahashi M, A oki S, et al. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies. J Exp Clin Cancer Res 1998; 17: 251-258.
34. Luczyński W, Stasiak-Barmuta A, Krawczuk-Rybak M, et al. Assessment of selected co-stimulatory, adhesion and activatory molecules and cytokines of Th(1)/Th(2) balance in acute lymphoblastic leukemia in children. Arch Immunol Ther Exp (Warsz) 2005; 53: 357-363.
35. Qi P, Ruan CP, Wang H, et al. CTLA-4+ 49A+ G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. Int J Colorectal Dis 2010; 25: 39-45.